- ICH GCP
- US Clinical Trials Registry
- Klinisk utprøving NCT07325617
Sporing av AI/LLM-ferdigheter og kunnskap i urologiske polikliniske pasienter (TALK-U) (TALK-U)
TALK-U-studien: Sporing av AI/LLM-kunnskap og bruk hos urologiske polikliniske pasienter og sammenhengen med angst, tilfredshet og helsebevissthet – en tverrsnittsstudie
This study is a one-time, questionnaire-based survey of adults attending a urology outpatient clinic. The investigators will examine whether patients who use AI chat tools based on large language models (LLMs), such as ChatGPT, before seeking care differ from non-users in (1) anxiety, (2) satisfaction with the clinic visit, and (3) awareness/understanding of their health condition.
Participants who provide written informed consent will complete a brief survey during their clinic visit (about 5-7 minutes). The survey includes a standardized anxiety scale (GAD-7), visual analog scales (0-10) for anxiety before and after the visit, satisfaction, and disease awareness, as well as questions about AI/LLM knowledge and use. Treating clinicians will not have access to participants' survey responses, and participation will not affect clinical care.
Studieoversikt
Status
Detaljert beskrivelse
The TALK-U study is a cross-sectional, observational survey conducted in the urology outpatient clinic of Dr. Abdurrahman Yurtaslan Ankara Oncology Training and Research Hospital. The primary exposure is self-reported AI/LLM knowledge and use for health information (e.g., whether participants have used ChatGPT or similar tools, frequency, awareness of AI, and purpose of use). The primary outcome is anxiety measured by GAD-7 at the time of the clinic encounter. Secondary outcomes include (i) anxiety assessed on a 0-10 visual analog scale before and after the visit, (ii) outpatient visit satisfaction (0-10 VAS), and (iii) perceived disease awareness/understanding (0-10 VAS).
Eligible adult first-time urology outpatients who can complete the survey independently and provide informed consent will be invited during a 2-month recruitment period. Analyses will compare outcomes between AI/LLM users and non-users and explore associations with age group (<40, 40-60, >60), education level, and urology subspecialty category. Data will be analyzed using appropriate parametric/nonparametric tests depending on distribution, with p < 0.05 considered statistically significant.
Studietype
Registrering (Faktiske)
Kontakter og plasseringer
Studiesteder
-
-
Yenimahalle/Ankara
-
Ankara, Yenimahalle/Ankara, Tyrkia (Türkiye), 06200
- Dr.Abdurrahman Yurtaslan Ankara Oncology Research and Training Hospital
-
-
Deltakelseskriterier
Kvalifikasjonskriterier
Alder som er kvalifisert for studier
Tar imot friske frivillige
Kjønn som er kvalifisert for studier
Prøvetakingsmetode
Studiepopulasjon
Adult patients (≥18 years) presenting for a first-time visit to the Urology Outpatient Clinic at Dr. Abdurrahman Yurtaslan Ankara Oncology Training and Research Hospital will be invited to participate during a 2-month recruitment period. Participants who provide written informed consent and can complete a brief questionnaire independently will be enrolled. The study will include both sexes and a broad range of urologic presenting complaints.
Beskrivelse
Inclusion Criteria:
- Age 18 years or older
- First-time visit to the Urology Outpatient Clinic
- Able to read and write and complete the questionnaire independently
- Able to provide written informed consent
Exclusion Criteria:
- Age under 18 years
- Insufficient literacy to understand and complete the questionnaire
- Severe hearing or visual impairment, or a neurological/psychiatric condition that prevents understanding and completing the survey
- Refusal or inability to provide informed consent
- Currently under follow-up for a known urologic condition (i.e., not a first-time urology outpatient visit)
Studieplan
Hvordan er studiet utformet?
Designdetaljer
- Observasjonsmodeller: CASE_CONTROL
- Tidsperspektiver: CROSS_SECTIONAL
Kohorter og intervensjoner
Gruppe / Kohort |
|---|
|
AI/LLM users
Participants who report prior use of AI chat tools based on large language models (e.g., ChatGPT or similar) for health information before the outpatient urology visit, as assessed by the study questionnaire. |
|
non AI/LLM users
Participants who report no prior use of AI/LLM chat tools (e.g., ChatGPT or similar) for health information before the outpatient urology visit, as assessed by the study questionnaire. |
Hva måler studien?
Primære resultatmål
Resultatmål |
Tiltaksbeskrivelse |
Tidsramme |
|---|---|---|
|
Pre-visit Anxiety (VAS 0-10)
Tidsramme: Day 0 (immediately before the outpatient visit)
|
Self-rated anxiety on a 0-10 visual analog scale (VAS), where 0 indicates no anxiety and 10 indicates the highest possible anxiety. This measure reflects visit-related state anxiety prior to clinician encounter. |
Day 0 (immediately before the outpatient visit)
|
Sekundære resultatmål
Resultatmål |
Tiltaksbeskrivelse |
Tidsramme |
|---|---|---|
|
Post-visit Anxiety (VAS 0-10)
Tidsramme: Day 0 (immediately after the outpatient visit)
|
Self-rated anxiety on a 0-10 VAS (0 = none, 10 = highest). |
Day 0 (immediately after the outpatient visit)
|
|
Visit Satisfaction (VAS 0-10)
Tidsramme: Day 0 (immediately after the outpatient visit)
|
Self-rated satisfaction with the outpatient visit on a 0-10 VAS (0 = not satisfied at all, 10 = maximum satisfaction). |
Day 0 (immediately after the outpatient visit)
|
|
Disease Awareness/Understanding (VAS 0-10)
Tidsramme: Day 0 (during the outpatient clinic visit)
|
Self-rated awareness/understanding of one's condition on a 0-10 VAS (0 = none, 10 = complete). |
Day 0 (during the outpatient clinic visit)
|
Andre resultatmål
Resultatmål |
Tiltaksbeskrivelse |
Tidsramme |
|---|---|---|
|
Baseline General Anxiety Symptoms (GAD-7 Total Score)
Tidsramme: Day 0 (at enrollment; prior to or during the clinic visit)
|
Total score on the 7-item GAD-7 questionnaire (range 0-21; higher scores indicate greater generalized anxiety symptoms). This measure will be used to account for baseline anxiety (trait-like symptoms) and to adjust analyses of VAS-based state anxiety out |
Day 0 (at enrollment; prior to or during the clinic visit)
|
Samarbeidspartnere og etterforskere
Studierekorddatoer
Studer hoveddatoer
Studiestart (Faktiske)
Primær fullføring (Faktiske)
Studiet fullført (Faktiske)
Datoer for studieregistrering
Først innsendt
Først innsendt som oppfylte QC-kriteriene
Først lagt ut (Faktiske)
Oppdateringer av studieposter
Sist oppdatering lagt ut (Faktiske)
Siste oppdatering sendt inn som oppfylte QC-kriteriene
Sist bekreftet
Mer informasjon
Begreper knyttet til denne studien
Nøkkelord
Ytterligere relevante MeSH-vilkår
Andre studie-ID-numre
- 2025-06/98
Legemiddel- og utstyrsinformasjon, studiedokumenter
Studerer et amerikansk FDA-regulert medikamentprodukt
Studerer et amerikansk FDA-regulert enhetsprodukt
Denne informasjonen ble hentet direkte fra nettstedet clinicaltrials.gov uten noen endringer. Hvis du har noen forespørsler om å endre, fjerne eller oppdatere studiedetaljene dine, vennligst kontakt register@clinicaltrials.gov. Så snart en endring er implementert på clinicaltrials.gov, vil denne også bli oppdatert automatisk på nettstedet vårt. .